REGISTERED NUMBER: 11158553 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

MED THERAPEUTICS LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTOR:

M D Upton

REGISTERED OFFICE:

Archer House

Britland Estate

Northbourne Road

Eastbourne

East Sussex

BN22 8PW

REGISTERED NUMBER:

11158553 (England and Wales)

ACCOUNTANTS:

Dominic Hill Associates Limited

Archer House

Britland Estate

Northbourne Road

Eastbourne

East Sussex

BN22 8PW

FIXED ASSETS

Tangible assets

4

18,274

21,951

CURRENT ASSETS

Stocks

549,491

444,166

Debtors

5

365,261

238,179

Cash at bank

352,133

370,578

1,266,885

1,052,923

CREDITORS

Amounts falling due within one year

6

667,687

717,632

NET CURRENT ASSETS

599,198

335,291

TOTAL ASSETS LESS CURRENT LIABILITIES

617,472

357,242

CAPITAL AND RESERVES

Called up share capital

500

500

Share premium

9,950

9,950

Retained earnings

607,022

346,792

SHAREHOLDERS' FUNDS

617,472

357,242

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 13 July 2026 and were signed by:

M D Upton - Director

1.	STATUTORY INFORMATION

Med Therapeutics Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc

-

25% on reducing balance

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

4.	TANGIBLE FIXED ASSETS

Plant and

machinery

etc

£

COST

At 1 January 2025

30,191

Additions

7,710

Disposals

(6,297

)

At 31 December 2025

31,604

DEPRECIATION

At 1 January 2025

8,240

Charge for year

6,091

Eliminated on disposal

(1,001

)

At 31 December 2025

13,330

NET BOOK VALUE

At 31 December 2025

18,274

At 31 December 2024

21,951

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade debtors

362,596

194,073

Other debtors

2,665

44,106

365,261

238,179

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade creditors

109,531

262,070

Taxation and social security

230,205

137,973

Other creditors

327,951

317,589

667,687

717,632

7.	DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

Included in creditors is an amount owed to the company Director. The amount has no fixed repayment date, and is interest free.

8.	RELATED PARTY DISCLOSURES

During the period the company undertook transactions with Attollo Health Ltd, a company controlled by M Upton, a company director.

The company was invoiced £50,400 (net) by Attollo Health Ltd for consultancy services.

The company was invoiced a further £96,295 (net) by Attollo Health Ltd for commission fees.

During the period the company also undertook transactions with MedicPartner GmbH, an overseas company controlled by Dr H Lorenz, a company director.

The company was invoiced £50,400 (net) by MedicPartner GmbH for management charges.

All related party transactions were at an arms length basis.

9.	ULTIMATE CONTROLLING PARTY

Dr H Lorenz controls the company by virtue of his 95% share holding of the company's issued share capital.